Profiling Drug Binding Properties
Accelerate Your Therapeutic Antibody Development with Precision Profiling
Offspring Biosciences empowers pharmaceutical and biotech innovators to de-risk and accelerate antibody drug development through advanced tissue-based binding property profiling. Leveraging over two decades of niche expertise, we deliver actionable insights into target engagement, safety, and efficacy—bridging the gap between preclinical discovery and clinical success.
Our specialized services combine analyses with multiplexed immunohistochemistry and in situ proximity ligation assay on high-quality and pathology pre-characterized human tissues, extended with AI-powered image analysis, to evaluate antibody behavior in disease-relevant microenvironments.
Unlike conventional CROs, we integrate antibody binding data, demonstration of target engagement with spatial biomarker analysis in the same tissue sample—a unique capability enhancing translational relevance. Clients like BioArctic leveraged our expertise to advance Leqembi®, the groundbreaking Alzheimer’s therapy, from target validation to regulatory approval.
ABETA TAU
From hit identification to clinical support.
We provide:
High-resolution on/off-target binding assessments to demonstrate target engagement and mitigate safety risks
Biomarker co-localization studies for validation of Mechanism of Actions (MoA) and patient stratification
Mechanistic insights into pharmacokinetic/pharmacodynamic relationships, epitope accessibility
Regulatory-ready datasets aligned with AstraZeneca’s 5R and Pfizer’s Three Pillars frameworks
Why partner with us?
Human Tissue Insights
Comprehensive analysis of antibody binding properties, on/off target engagement and biomarker expression in human tissues (both normal and disease).
Proven Track Record
A specialized CRO since 2012. Offspring Biosciences supports pharmaceutical and biotech companies with advanced tissue-based analytics to accelerate drug development.
Pharma background
Our team brings extensive experience from AstraZeneca, combining deep industry knowledge with cutting-edge molecular pathology techniques.
Tailored solutions
We offer flexible, customized services to overcome challenges in antibody drug development, enhacing clinical success rates.